Year in Review: Chronic Lymphocytic Leukemia

(MedPage Today) -- Studies on chronic lymphocytic leukemia (CLL) over the past year have demonstrated that Bruton tyrosine kinase (BTK) inhibitor-based combinations improve prognosis, and second-generation BTK inhibitors are more tolerable.
In...